查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2048145

馬用藥品及補充品市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、通路、地區和競爭格局分類，2021-2031年

Equine Pharmaceuticals & Supplements Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球馬用藥品和補充劑市場預計將從 2025 年的 9.9391 億美元成長到 2031 年的 14.0828 億美元，複合年成長率達到 5.98%。

該領域涵蓋獸藥，例如疫苗和感染疾病物，以及旨在改善動物健康和運動表現的營養補充劑。推動這一領域擴張的關鍵因素包括全球馬術比賽參與人數的不斷成長，以及馬主在預防性醫療保健和馬匹福利方面投入的增加。這一成長得益於強大的專業群體，他們尋求持續的獸醫支持以確保馬匹做好參賽準備。國際馬術聯合會 (FEI) 的 2025 年資料庫顯示，這項高度依賴這些醫療保健解決方案的高性能市場規模龐大，預計將有 490,362 匹活躍馬匹。然而，阻礙市場擴張的一大挑戰是動物用藥品核准和商業化的嚴格法律制度。複雜的合規要求和嚴格的安全標準需要大量的資金投入和漫長的研發週期，這往往會扼殺創新，並延緩先進治療方法在發展中地區的應用。

市場概覽
預測期 2027-2031
市場規模：2025年 9.9391億美元
市場規模：2031年 14.0828億美元
複合年成長率：2026-2031年 5.98%
成長最快的細分市場 製藥
最大的市場 北美洲

市場促進因素

全球對馬術運動和賽馬運動日益成長的興趣是推動市場成長的主要動力，也因此對增強運動表現的營養補充劑和先進的獸醫護理產生了顯著的需求。隨著職業比賽總獎金的增加，馬主和練馬師正大力投資於藥物治療方案，以確保高水平賽馬的最佳健康狀態、加速康復和有效緩解疼痛。這項投資與產業的盈利密切相關。維持賽馬的競爭優勢至關重要，英國賽馬協會（BHA）在2025年3月宣布，將為88場訓練賽提供超過330萬英鎊的獎金，便是最好的例證。這促使人們採取嚴格的健康管理措施來贏得這些豐厚的獎金。同時，馬匹感染疾病和慢性疾病的日益普遍也要求疫苗、抗生素和特定治療方案的持續研發和應用。公共馬厩和國際運輸過程中病毒和細菌感染疾病的頻繁爆發迫使相關人員優先考慮預防保健和快速治療性介入，以避免大規模突發公共衛生事件的發生。例如，賓州州立大學推廣中心2025年12月發布的一份報告強調了強力的疾病控制方案的必要性，並列舉了一次疫情中確診的47例馬皰疹性腦脊髓炎（EHM）病例。勃林格殷格翰2025年的報告也進一步反映了對健康相關產品的廣泛需求，該報告指出，在抗寄生蟲藥和治療藥物強勁銷售的推動下，該公司動物保健業務上半年淨銷售額達26億歐元。

市場挑戰

動物用藥品核准的嚴格監管環境對全球馬用藥品和營養補充品市場的成長構成重大障礙。製造商必須遵守一系列複雜的規定，包括廣泛的臨床試驗、強制性的藥物安全監測和嚴格的安全標準，以獲得市場核准。這一冗長而繁瑣的流程不可避免地延長了研發週期，導致關鍵療法上市時間大幅延遲。因此，新產品上市速度緩慢限制了產品系列的擴展，阻礙了產業快速應對新出現的馬匹健康問題的能力，並削弱了市場動態。此外，這些監管規定要求巨額資金投入，也構成了市場准入的巨大壁壘，扼殺了創新，並將市場參與者主要限制在資金雄厚的大型企業。龐大的前期投資需求擠佔了原本可用於探索性研究和市場多元化的資金。這一巨大的財政負擔清晰地反映在該行業的績效指標中。根據歐洲動物保健協會（AnimalhealthEurope）報告，為跟上不斷變化的標準，2024年研發投入超過6.49億美元。如此龐大的資金需求不僅阻礙了小規模、更靈活的競爭對手進入市場，也使得價格敏感型發展中地區難以採用先進解決方案，因為高昂的合規成本可能導致投資回報不切實際。

市場趨勢

人工智慧驅動的診斷技術與穿戴式健康監測的融合正在革新馬匹護理，使人們能夠在生理異常發展成嚴重損傷之前即時識別它們。相關人員擴大利用生物感測器和步態分析平台來收集心率變異性和步態對稱性等持續性數據，從而將重點從被動治療轉向主動預防損傷。這項技術進步得到了強大的機構支持。例如，美國馬醫學會 (AAEP) 於 2024 年 11 月宣布了一項計劃，該計劃由 10 個組織共同出資 78.5 萬美元，用於資助一項針對 600 匹純種馬的穿戴式技術綜合研究。同時，市場也呈現向個人化馬匹營養和精準醫療發展的明顯趨勢，其特點是轉向使用科學配方以滿足特定代謝需求的優質飼料。隨著人們對馬匹微生物組的了解不斷加深，以及對延長馬匹壽命的營養干預措施需求日益成長，馬主和馴馬師越來越傾向於選擇能夠最佳化腸道健康和「潔淨標示」飼料的解決方案，而非傳統的批量生產飼料。這種向高品質、專業化營養的轉變也影響著飼料生產。 Alltek 發布的 2025 年 4 月《農業食品展望》報告指出，到 2024 年，全球馬飼料產量將增加 2.3%，達到 963 萬噸。這一成長主要歸因於市場對優質化營養護理產品的需求不斷成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：馬用藥品和補充劑的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（藥品、保健品）
    • 銷售管道（藥局、獸醫診所等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美馬用藥品和補充劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲馬用藥品和補充劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區馬用藥品和補充劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲馬用藥品和補充品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲馬用藥品和補充劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球馬用藥品和補充劑市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Zoetis Inc
  • Boehringer Ingelheim GmbH
  • Merck & Co Inc
  • Elanco Animal Health Inc
  • Bayer AG
  • Ceva Sante Animale SA
  • Virbac SA
  • Vetoquinol SA
  • Affymetrix Inc
  • Celltrion Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18814

The Global Equine Pharmaceuticals & Supplements Market is forecast to grow from USD 993.91 Million in 2025 to USD 1408.28 Million by 2031, achieving a 5.98% CAGR. This sector covers veterinary medicinal products such as vaccines and anti-infectives, alongside nutritional supplements, all formulated to enhance animal health and physical performance. The primary drivers behind this expansion include increasing global participation in organized equestrian sports and greater owner investment in preventive healthcare and welfare. This growth is bolstered by a robust professional segment that demands consistent veterinary support to ensure competitive readiness. The substantial scale of this high-performance market, heavily reliant on these health solutions, is evidenced by the Federation Equestre Internationale, which reported 490,362 active horse entries in its 2025 database. However, a significant challenge impeding market expansion is the stringent regulatory environment governing veterinary drug approval and commercialization. The complex compliance requirements and rigorous safety standards necessitate extensive capital investment and prolonged development timelines, often hindering innovation and delaying advanced therapeutic treatments in developing regions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 993.91 Million
Market Size 2031USD 1408.28 Million
CAGR 2026-20315.98%
Fastest Growing SegmentPharmaceutical
Largest MarketNorth America

Market Driver

Increasing global engagement in equestrian sports and horse racing serves as a significant impetus for market growth, generating considerable demand for performance-enhancing supplements and advanced veterinary treatments. As professional competition stakes rise, owners and trainers are making substantial financial investments in pharmaceutical programs to ensure optimal physical condition, expedite recovery, and effectively manage pain in high-performance equines. This financial dedication is intrinsically tied to the industry's profitability, where preserving a horse's competitive advantage is crucial, exemplified by the British Horseracing Authority's March 2025 announcement of over £3.3 million in prize money across 88 developmental races, which encourages stringent health management to secure these lucrative rewards. Concurrently, a growing prevalence of equine infectious diseases and chronic conditions mandates the ongoing innovation and acquisition of vaccines, antibiotics, and specific treatment protocols. Frequent outbreaks of viral and bacterial infections, often occurring in communal stabling or during international transport, compel stakeholders to prioritize both preventative care and prompt therapeutic interventions to avert widespread health emergencies. For example, a Penn State Extension report from December 2025 highlighted 47 confirmed cases of Equine Herpes Myeloencephalopathy (EHM) from a single outbreak, emphasizing the vital need for robust disease management solutions. The extensive demand for such health products is further reflected in Boehringer Ingelheim's 2025 report, which cited net sales of EUR 2.6 billion from its Animal Health business in the first half of the year, driven by steady sales of its parasiticides and therapeutic range.

Market Challenge

The rigorous regulatory landscape for veterinary drug approval presents a significant obstacle to the growth of the Global Equine Pharmaceuticals & Supplements Market. Manufacturers must comply with an intricate web of requirements, including extensive clinical trials, pharmacovigilance mandates, and strict safety standards, to obtain market authorization. This lengthy bureaucratic process invariably extends development timelines, leading to considerable delays in bringing essential therapeutic treatments to market. The resulting slow introduction of new products limits portfolio expansion, hindering the industry's capacity to quickly address new equine health issues and diminishing overall market dynamism. Moreover, the substantial financial demands imposed by these regulations establish formidable barriers to market entry, stifling innovation and limiting participation primarily to well-capitalized corporations. The requirement for massive upfront resource allocation diverts funds that could otherwise be directed towards exploratory research or market diversification. This considerable financial strain is evident in the sector's operational figures, with AnimalhealthEurope reporting over USD 649 million invested in research and development in 2024 to meet evolving standards. These extensive capital requirements not only prevent smaller, more agile competitors from entering the market but also discourage the introduction of advanced solutions in price-sensitive developing regions where high compliance costs may not justify the potential return on investment.

Market Trends

The integration of AI-driven diagnostics and wearable health monitoring is revolutionizing equine care by facilitating the real-time identification of physiological irregularities before they develop into severe injuries. Industry stakeholders are increasingly utilizing biometric sensors and gait analysis platforms to collect continuous data, such as heart rate variability and stride symmetry, shifting the focus from reactive treatments to proactive injury prevention. This technological evolution is supported by substantial institutional backing, exemplified by the American Association of Equine Practitioners (AAEP)'s November 2024 announcement, where ten organizations collectively pledged USD 785,000 to fund a comprehensive study assessing wearable technologies on 600 thoroughbreds. Concurrently, the market is observing a clear trend towards personalized equine nutrition and precision medicine, marked by a move to premium, scientifically formulated feeds tailored to specific metabolic requirements. Owners and trainers are increasingly opting for optimized gut health solutions and "clean-label" diets over conventional bulk feeds, driven by enhanced understanding of the equine microbiome and a desire to extend longevity through targeted nutritional interventions. This shift towards high-quality, specialized nutrition is impacting production, with Alltech's April 2025 'Agri-Food Outlook' report noting a 2.3% increase in global equine feed tonnage to 9.63 million metric tons in 2024, a rise specifically attributed to premiumization and heightened demand for nutrition-focused care.

Key Market Players

  • Zoetis Inc
  • Boehringer Ingelheim GmbH
  • Merck & Co Inc
  • Elanco Animal Health Inc
  • Bayer AG
  • Ceva Sante Animale SA
  • Virbac SA
  • Vetoquinol SA
  • Affymetrix Inc
  • Celltrion Inc

Report Scope

In this report, the Global Equine Pharmaceuticals & Supplements Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Equine Pharmaceuticals & Supplements Market, By Product

  • Pharmaceutical
  • Supplement

Equine Pharmaceuticals & Supplements Market, By Distribution Channel

  • Drug Stores
  • Veterinary Hospitals
  • Others

Equine Pharmaceuticals & Supplements Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Equine Pharmaceuticals & Supplements Market.

Available Customizations:

Global Equine Pharmaceuticals & Supplements Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Equine Pharmaceuticals & Supplements Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Pharmaceutical, Supplement)
    • 5.2.2. By Distribution Channel (Drug Stores, Veterinary Hospitals, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Equine Pharmaceuticals & Supplements Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Equine Pharmaceuticals & Supplements Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Equine Pharmaceuticals & Supplements Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Equine Pharmaceuticals & Supplements Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Distribution Channel

7. Europe Equine Pharmaceuticals & Supplements Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Equine Pharmaceuticals & Supplements Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Equine Pharmaceuticals & Supplements Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Equine Pharmaceuticals & Supplements Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Equine Pharmaceuticals & Supplements Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Equine Pharmaceuticals & Supplements Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Equine Pharmaceuticals & Supplements Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Equine Pharmaceuticals & Supplements Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Equine Pharmaceuticals & Supplements Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Equine Pharmaceuticals & Supplements Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Equine Pharmaceuticals & Supplements Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Equine Pharmaceuticals & Supplements Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Equine Pharmaceuticals & Supplements Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Equine Pharmaceuticals & Supplements Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Equine Pharmaceuticals & Supplements Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Equine Pharmaceuticals & Supplements Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Distribution Channel

10. South America Equine Pharmaceuticals & Supplements Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Equine Pharmaceuticals & Supplements Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Equine Pharmaceuticals & Supplements Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Equine Pharmaceuticals & Supplements Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Equine Pharmaceuticals & Supplements Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Zoetis Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Boehringer Ingelheim GmbH
  • 15.3. Merck & Co Inc
  • 15.4. Elanco Animal Health Inc
  • 15.5. Bayer AG
  • 15.6. Ceva Sante Animale SA
  • 15.7. Virbac SA
  • 15.8. Vetoquinol SA
  • 15.9. Affymetrix Inc
  • 15.10. Celltrion Inc

16. Strategic Recommendations

17. About Us & Disclaimer